InsidersTradesSigma
Follow the NeuroPace Inc stock price and the full insider trade history of the company, a listed equity based in United States. Shares are quoted on the US market, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, NeuroPace Inc has recorded 105 public disclosures. Market capitalisation: €485m. The latest transaction was filed on 28 August 2026 (Retenue fiscale). Among the most active insiders: Morrell Martha. Every trade is accessible without an account.
105
Insider Decl.
n/a
Thresholds
€475,768
1 ops.
Buy Volume
€59m
27 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate NeuroPace Inc Strong Buy (bullish), based on 9 analysts. Average price target: US$20.22.
33Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 23,570 of 29,062 companies
29.9
score / 100
Value27
Quality33
FCF yld-2.3%
Earn yld-4.3%
EV/EBITDA·
ROE-103%
Gross mgn77%
Net mgn-21%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 28 August 2026
Declarations105 total
358 shares@ US$14.13Common StockSEC:0001855616-26-000022:0
1,126 shares@ US$14.13Common StockSEC:0001533175-26-000014:0
335 sharesCommon StockSEC:0001855616-26-000019:0
2,890 shares0Common StockSEC:0001595202-26-000002:0
1,255 shares@ US$15.880.0031% mcap19.6% of flowCommon StockSEC:0001533175-26-000011:0
1,126 shares@ US$17.060.0032% mcap23.4% of flowCommon StockSEC:0001533175-26-000009:0
1,341 shares@ US$13.270.9% of flowCommon StockSEC:0001855616-26-000011:0
913 shares@ US$13.0051.5% of flowCommon StockSEC:0001628280-26-020837:0
865 shares@ US$13.0048.4% of flowCommon StockSEC:0001628280-26-020835:0
1,153 shares@ US$13.0048.4% of flowCommon StockSEC:0001856296-26-000003:0
1,826 shares@ US$13.0052.6% of flowCommon StockSEC:0001297260-26-000003:0
25,000 shares@ US$15.9715.8% of flowCommon StockSEC:0001855616-26-000007:0
5,023 shares@ US$13.8332.0% of flowCommon StockSEC:0001533175-26-000004:0
358 shares@ US$14.580.2% of flowCommon StockSEC:0001855616-26-000005:0
1,126 shares@ US$14.587.5% of flowCommon StockSEC:0001533175-26-000002:0
3,412 shares@ US$14.341.9% of flowCommon StockSEC:0001855616-26-000003:0
904 shares@ US$16.5924.5% of flowCommon StockSEC:0001856296-25-000005:0
715 shares@ US$16.5925.2% of flowCommon StockSEC:0001467361-25-000005:0
1,431 shares@ US$16.5925.5% of flowCommon StockSEC:0001297260-25-000006:0
678 shares@ US$16.5924.5% of flowCommon StockSEC:0001215490-25-000007:0
1,338 shares@ US$16.661.1% of flowCommon StockSEC:0001855616-25-000007:0
357 shares@ US$16.500.3% of flowCommon StockSEC:0001855616-25-000005:0
1,126 shares@ US$16.5014.3% of flowCommon StockSEC:0001533175-25-000004:0
3,051 shares@ US$13.502.1% of flowCommon StockSEC:0001855616-25-000003:0
1,509 shares@ US$9.9432.2% of flowCommon StockSEC:0001856296-25-000003:0
25 of 105 declarations
关于 NeuroPace Inc
NeuroPace Inc.（股票代码：NPCE）是一家总部位于美国、在美国纳斯达克股票市场上市的医疗设备公司。公司总部位于加利福尼亚州山景城，专注于癫痫护理，特别是通过个性化脑神经调节治疗耐药性癫痫发作。其核心业务围绕 RNS® 系统（响应性神经刺激系统），NeuroPace 将其描述为首个也是唯一一个可商用的脑响应平台，能够实时在癫痫发作源头提供治疗。对于法国、比利时和瑞士投资者而言，NeuroPace 最好被视为一家专业的医疗技术公司，在一个专注但高价值的治疗利基市场中拥有差异化的临床主张。（[neuropace.com](https://www.neuropace.com/about-neuropace/?utm_source=openai)） 从历史角度看，根据公司文件，NeuroPace 成立于 1997 年。该公司随后在 2021 年 4 月以 NPCE 股票代码在纳斯达克首次公开募股，达到了一个重要的里程碑，标志着从开发阶段公司向拥有既定收入基础的商业阶段平台的转型。其总部仍位于加利福尼亚州山景城，使其处于硅谷创新生态系统之中。（[investors.neuropace.com](https://investors.neuropace.com/static-files/420792b5-64c9-471a-be3c-de87f16f5f88?utm_source=openai)） 在运营方面，NeuroPace 的大部分收入来自 RNS 系统，这是一种植入式设备，可监测大脑活动并提供有针对性的电刺激，以减少选定患有局灶性癫痫的成年患者的癫痫发作。该公司还强调了旨在简化护理的产品增强功能，以及旨在改善癫痫管理的数据和人工智能相关举措。2025 年，NeuroPace 宣布重新调整其产品组合，这表明其将更集中于其核心癫痫业务和最具战略相关性的增长机会。（[neuropace.com](https://www.neuropace.com/about-neuropace/?utm_source=openai)） 在竞争方面，NeuroPace 占据着高度专业化的地位，而不是作为一家广泛的医疗技术巨头进行竞争。其关键优势在于植入技术、持续脑数据捕获和个性化治疗的结合，这一主张是竞争对手难以快速复制的。同时，该公司在一个要求严苛的市场中运营，临床证据、医生采纳和报销至关重要。最近的披露显示出积极的商业势头：在 2026 年第一季度，收入有所增长，这得益于 RNS 系统销量的增加，管理层上调了 2026 年全年收入指导。NeuroPace 还在 2025 年初完成了 65 million 美元的普通股发行，这突显了积极的资产负债表管理以及与增长和产品开发相关的资金需求。（[investors.neuropace.com](https://investors.neuropace.com/news/news-details/2026/NeuroPace-Reports-First-Quarter-2026-Financial-Results-and-Raises-2026-Revenue-Guidance/?utm_source=openai)） 总的来说，NeuroPace 是一家在纳斯达克上市的美国小型医疗技术公司，专注于癫痫创新，其商业模式围绕着一款旗舰设备、一个明确的临床利基市场以及与 RNS 增长、潜在适应症扩展和财务纪律相关的近期催化剂。（[investors.neuropace.com](https://investors.neuropace.com/news/news-details/2026/NeuroPace-Reports-First-Quarter-2026-Financial-Results-and-Raises-2026-Revenue-Guidance/?utm_source=openai)）
